Philippe Tessier studied at Laval University, the John Curtin School of Medical Research (Australian National University) and the University of Adelaide, followed by a post-doctoral fellowship at the Imperial Cancer Research Fund (United Kingdom). He has been a researcher at the Centre de recherche du CHU de Québec – Laval University since 1999, and a professor at the Department of Microbiology-Infectiology and Immunology of the Laval University School of Medicine.
Research Projects
Professor Tessier studies the biological activities of the proteins S100A8 and S100A9, two small proteins expressed by neutrophils, monocytes, and activated endothelial and epithelial cells. These proteins are secreted during inflammation and activate the immune response. His research indicates that S100A8 and S100A9 have opposite functions: S100A8 is anti-inflammatory and inhibits myeloid cell differentiation, while S100A9 is pro-inflammatory and induces the differentiation of precursors of neutrophils and monocytes. He studies the roles of these proteins in autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease, in immune responses to solid tumors, and in the differentiation of leukemia cells.
Auto-inflammatory diseases are monogenic orphan diseases (<10,000 cases per syndrome worldwide) usually caused by defects in the genes regulating innate immunity. These diseases are characterized by recurrent, unprovoked inflammation (fever, abdominal pain, rash, arthralgia). High plasma concentrations of S100A8 and S100A9 are often found in patients with auto-inflammatory diseases. In collaboration with Professor Martin Pelletier and Dr. Anne-Laure Chetaille, Prof. Tessier is currently studying the roles of S100A8 and S100A9 in these diseases, to develop a diagnostic test to facilitate the treatment of these patients.
2705, boulevard Laurier
RC-709
Québec, Québec
Canada G1V 4G2
Latest news
Data not available
The use of leukocytes' secretome to individually target biological therapy in autoimmune arthritis: a case report.
Journal ArticleClin Transl Med, 8 (1), pp. 19, 2019, ISSN: 2001-1326.
Abstract | Links: 
Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis.
Journal ArticleCancer Res, 79 (4), pp. 795-806, 2019, ISSN: 0008-5472.
Abstract | Links:
Enhanced myelopoiesis and aggravated arthritis in S100a8-deficient mice.
Journal ArticlePLoS ONE, 14 (8), pp. e0221528, 2019.
Abstract | Links:
Regulation of S100A8 Stability by RNF5 in Intestinal Epithelial Cells Determines Intestinal Inflammation and Severity of Colitis.
Journal ArticleCell Rep, 24 (12), pp. 3296-3311.e6, 2018.
Abstract | Links:
Quinoline-3-carboxamides such as tasquinimod are not specific inhibitors of S100A9.
Journal ArticleBlood Adv, 2 (10), pp. 1170-1171, 2018, ISSN: 2473-9529.
| Links:
S100A8/A9 and sRAGE kinetic after polytrauma; an explorative observational study.
Journal ArticleScand J Trauma Resusc Emerg Med, 25 (1), pp. 114, 2017.
Abstract | Links:
S100A9 induces differentiation of acute myeloid leukemia cells through TLR4.
Journal ArticleBlood, 129 (14), pp. 1980-1990, 2017, ISSN: 0006-4971.
Abstract | Links:
S100A9 potentiates the activation of neutrophils by the etiological agent of gout, monosodium urate crystals.
Journal ArticleJ Leukoc Biol, 102 (3), pp. 805-813, 2017, ISSN: 0741-5400.
Abstract | Links:
IL-23 induced in keratinocytes by endogenous TLR4 ligands polarizes dendritic cells to drive IL-22 responses to skin immunization.
Journal ArticleJ Exp Med, 213 (10), pp. 2147-66, 2016, ISSN: 0022-1007.
Abstract | Links:
Discoidin domain receptor 1 promotes Th17 cell migration by activating the RhoA/ROCK/MAPK/ERK signaling pathway.
Journal ArticleOncotarget, 7 (29), pp. 44975-44990, 2016, ISSN: 1949-2553.
Abstract | Links:
Active projects
- Biology of S100A8 and S100A9 proteins in Human Acute Myeloid Leukemia, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2019-10-01 to 2024-09-30
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- The characterization of MICL, a novel negative regulator of the immune response in arthritis., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2020-06-30
Recently finished projects
- Centre de recherche en arthrite de l'Université Laval, Subvention, Institutionnel - BDR, BDR - Entités de recherche en émergence, from 2019-01-01 to 2020-01-31
- Immunosuppressive function of S100A8 in arthritis., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2014-07-01 to 2019-06-30
- Soutien des travaux de recherche sur les maladies infectieuses et immunitaires, Subvention, Fondation du CHU de Québec, from 2018-04-01 to 2019-03-31